All News
SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus
One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs).
Read Article
mTOR Inhibition with Sirolimus Effective in Lupus
Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.
Read Article
Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept
The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T
Read Article
Steroid Use During Rheumatoid Pregnancies
Pregnant women (n=254) with rheumatoid arthritis who enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study and who were taking oral glucocorticoids were studied.
Read Article
2017 Rheumatology Year in Review
This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017. In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.
Read Article
IL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).
Read Article
Shorter Steroid Courses Effective in ANCA+ Vasculitis
An 8-week course of prednisone plus rituximab (Rituxin) offered good outcomes in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including complete remission, researchers reported.
Read Article
ASCO/NCCN Guidelines for Checkpoint Inhibitor Immune-Related Adverse Events
New guidelines have been developed by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) on how to assess and manage of immune checkpoint inhibitor side effects that are often autoimmune in nature.
Read Article
Apremilast Continues to Look Good in Behcet's Disease
The 2018 American Academy of Dermatology Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.
Read Article
RWCS Day 4 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui, with excerpts from leading teachers in rheumatology. This podcast features presentations from Drs.
Read Article
RWCS Day 3 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features topics in dermatology, the fellowship program lead by Dr. Bernie Rubin and videos by the fellows. Featured are Drs.
Read Article
The RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read Article
RWCS Day 2 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features Drs. Martin Bergman, Jack Cush, Rachel Tate, Phil Aleksiejuk, Shubha Kollampare, Orrin Troum, and Alvin Wells. Listen here or on Stitcher, iTune, iPhone, Soundcloud or Google play.
Read Article
The RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read Article
ESRD Death Declines in Vasculitis Patients
In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.
Read Article
Higher Fracture Risk with PMR and GCA
Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.
Read Article
The RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read Article
The RheumNow Week in Review - 12 January 2018
Dr. Jack Cush reviews a dozen highlights from the past week on RheumNow.com.
Read Article
Registry Efficacy of Rituximab in Refractory SLE
Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR, EXPLORER), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.
Read Article
Advantages of Intravenous Pulse Cyclophosphamide in ANCA-associated Vasculitis
Researchers from the Nottingham University Hospitals have analyzed the efficacy and safety of oral (PO) and intravenous (IV) cyclophosphamide (CTX) in ANCA-associated vasculitis (AAV) patients and demonstrated a trend for fewer relapses, better 1 year survival and less toxicity w
Read Article
